Compare ALRS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALRS | ACRS |
|---|---|---|
| Founded | 1879 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 831.8M | 868.5M |
| IPO Year | 2019 | 2015 |
| Metric | ALRS | ACRS |
|---|---|---|
| Price | $31.95 | $5.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $25.40 | $10.20 |
| AVG Volume (30 Days) | 121.0K | ★ 2.4M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ 1.70 | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $38.42 | N/A |
| Revenue Next Year | $4.68 | $4.24 |
| P/E Ratio | $18.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.31 | $1.74 |
| 52 Week High | $34.40 | $6.60 |
| Indicator | ALRS | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 33.98 | 41.16 |
| Support Level | $30.13 | $4.99 |
| Resistance Level | $31.86 | $5.83 |
| Average True Range (ATR) | 0.69 | 0.35 |
| MACD | -0.15 | -0.04 |
| Stochastic Oscillator | 0.00 | 24.68 |
Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and others. The company provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services and wealth management services, including retirement plans, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.